Accelerate Diagnostics Company Profile (NASDAQ:AXDX)

About Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics logoAccelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $1.48 billion
  • Outstanding Shares: 52,034,000
Average Prices:
  • 50 Day Moving Avg: $26.29
  • 200 Day Moving Avg: $23.85
  • 52 Week Range: $10.87 - $29.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -30.87
  • P/E Growth: -0.79
Sales & Book Value:
  • Annual Revenue: $612,999.00
  • Price / Sales: 2,410.71
  • Book Value: $1.33 per share
  • Price / Book: 21.35
Profitability:
  • EBIDTA: ($63,330,000.00)
  • Net Margins: -27,686.46%
  • Return on Equity: -56.50%
  • Return on Assets: -53.72%
Debt:
  • Current Ratio: 20.65%
  • Quick Ratio: 20.65%
Misc:
  • Average Volume: 359,332 shs.
  • Beta: 1.01
  • Short Ratio: 23.98
 

Frequently Asked Questions for Accelerate Diagnostics (NASDAQ:AXDX)

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics Inc (NASDAQ:AXDX) released its earnings results on Friday, May, 5th. The company reported ($0.27) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.34) by $0.07. The business had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.60 million. Accelerate Diagnostics had a negative net margin of 27,686.46% and a negative return on equity of 56.50%. View Accelerate Diagnostics' Earnings History.

What guidance has Accelerate Diagnostics issued on next quarter's earnings?

Accelerate Diagnostics updated its first quarter earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of ($0.27) for the period, compared to the Thomson Reuters consensus estimate of ($0.35). The company issued revenue guidance of $530000, compared to the consensus revenue estimate of $1.31 million.

Where is Accelerate Diagnostics' stock going? Where will Accelerate Diagnostics' stock price be in 2017?

2 brokers have issued twelve-month price objectives for Accelerate Diagnostics' shares. Their predictions range from $25.00 to $34.00. On average, they expect Accelerate Diagnostics' stock price to reach $29.50 in the next twelve months. View Analyst Ratings for Accelerate Diagnostics.

Are investors shorting Accelerate Diagnostics?

Accelerate Diagnostics saw a increase in short interest in April. As of April 13th, there was short interest totalling 9,483,289 shares, an increase of 2.9% from the March 31st total of 9,216,508 shares. Based on an average daily trading volume, of 214,236 shares, the short-interest ratio is presently 44.3 days.

Who are some of Accelerate Diagnostics' key competitors?

Who owns Accelerate Diagnostics stock?

Accelerate Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Birchview Capital LP (4.21%), Vanguard Group Inc. (0.00%), Blair William & Co. IL (0.00%), Loomis Sayles & Co. L P (0.00%), Credit Suisse AG (0.79%) and Selkirk Management LLC (0.77%). Company insiders that own Accelerate Diagnostics stock include Brink Frank Jm Ten, Jack W Schuler, Larry N Feinberg, Lawrence Mehren and Matthew Strobeck. View Institutional Ownership Trends for Accelerate Diagnostics.

Who sold Accelerate Diagnostics stock? Who is selling Accelerate Diagnostics stock?

Accelerate Diagnostics' stock was sold by a variety of institutional investors in the last quarter, including Next Century Growth Investors LLC, Tekla Capital Management LLC, Morgan Stanley, TIAA CREF Investment Management LLC, Alliancebernstein L.P., Parametric Portfolio Associates LLC, California Public Employees Retirement System and Metropolitan Life Insurance Co. NY. View Insider Buying and Selling for Accelerate Diagnostics.

Who bought Accelerate Diagnostics stock? Who is buying Accelerate Diagnostics stock?

Accelerate Diagnostics' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Credit Suisse AG, Kornitzer Capital Management Inc. KS, Loomis Sayles & Co. L P, Vanguard Group Inc., Credit Agricole S A, Blair William & Co. IL and Selkirk Management LLC. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Brink Frank Jm Ten, Jack W Schuler, Larry N Feinberg and Matthew Strobeck. View Insider Buying and Selling for Accelerate Diagnostics.

How do I buy Accelerate Diagnostics stock?

Shares of Accelerate Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Accelerate Diagnostics stock cost?

One share of Accelerate Diagnostics stock can currently be purchased for approximately $28.40.

Analyst Ratings

Consensus Ratings for Accelerate Diagnostics (NASDAQ:AXDX) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $29.50 (3.87% upside)

Analysts' Ratings History for Accelerate Diagnostics (NASDAQ:AXDX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/17/2017BTIG ResearchReiterated RatingBuy$34.00HighView Rating Details
8/9/2016JPMorgan Chase & Co.Boost Price TargetOverweight$17.00 -> $25.00N/AView Rating Details
5/16/2016Piper Jaffray CompaniesReiterated RatingOverweight$25.00N/AView Rating Details
1/29/2016William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Accelerate Diagnostics (NASDAQ:AXDX)
Earnings by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
Earnings History by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2017Q1($0.34)($0.27)$0.60 million$0.50 millionViewListenView Earnings Details
2/27/2017Q4 2016($0.35)($0.31)$0.24 million$0.04 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.35)($0.34)$0.02 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Accelerate Diagnostics (NASDAQ:AXDX)
2017 EPS Consensus Estimate: ($1.29)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.34)($0.34)($0.34)
Q2 20171($0.34)($0.34)($0.34)
Q3 20171($0.31)($0.31)($0.31)
Q4 20171($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Accelerate Diagnostics (NASDAQ:AXDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Accelerate Diagnostics (NASDAQ:AXDX)
Insider Ownership Percentage: 51.40%
Institutional Ownership Percentage: 37.35%
Insider Trades by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
Insider Trades by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Lawrence MehrenInsiderSell400,068$19.00$7,601,292.00View SEC Filing  
1/9/2017Matthew StrobeckDirectorBuy8,000$19.00$152,000.00View SEC Filing  
6/30/2016Jack W SchulerDirectorBuy90,147$13.95$1,257,550.65View SEC Filing  
6/14/2016Jack W SchulerDirectorBuy14,033$13.67$191,831.11View SEC Filing  
6/13/2016Jack W SchulerDirectorBuy15,967$13.70$218,747.90View SEC Filing  
6/10/2016Jack W SchulerDirectorBuy88,316$14.69$1,297,362.04View SEC Filing  
6/9/2016Jack W SchulerDirectorBuy101,272$14.14$1,431,986.08View SEC Filing  
5/20/2016Jack W SchulerDirectorBuy4,270$11.04$47,140.80View SEC Filing  
5/17/2016Jack W SchulerDirectorBuy10,000$11.45$114,500.00View SEC Filing  
5/16/2016Jack W SchulerDirectorBuy11,511$11.91$137,096.01View SEC Filing  
5/13/2016Jack W SchulerDirectorBuy20,000$12.45$249,000.00View SEC Filing  
2/9/2016Jack W SchulerDirectorBuy600,000$11.86$7,116,000.00View SEC Filing  
2/8/2016Jack W SchulerDirectorBuy20,000$12.32$246,400.00View SEC Filing  
2/5/2016Jack W SchulerDirectorBuy7,308$12.65$92,446.20View SEC Filing  
2/4/2016Jack W SchulerDirectorBuy10,000$12.98$129,800.00View SEC Filing  
2/3/2016Jack W SchulerDirectorBuy50,100$13.09$655,809.00View SEC Filing  
2/2/2016Jack W SchulerDirectorBuy20,000$13.46$269,200.00View SEC Filing  
1/21/2016Jack W SchulerDirectorBuy10,000$15.02$150,200.00View SEC Filing  
12/10/2015Larry N FeinbergMajor ShareholderBuy117,647$17.00$1,999,999.00View SEC Filing  
11/5/2015Jack W SchulerDirectorBuy11,899$16.81$200,022.19View SEC Filing  
11/4/2015Jack W SchulerDirectorBuy52,837$16.81$888,189.97View SEC Filing  
10/22/2015Jack W SchulerDirectorBuy2,160$15.82$34,171.20View SEC Filing  
9/29/2015Brink Frank Jm TenDirectorBuy9,800$15.24$149,352.00View SEC Filing  
8/26/2015Jack W SchulerDirectorBuy10,000$17.81$178,100.00View SEC Filing  
8/25/2015Jack W SchulerDirectorBuy10,000$18.56$185,600.00View SEC Filing  
4/17/2015Jack W SchulerDirectorBuy11,000$21.94$241,340.00View SEC Filing  
3/19/2015Matthew StrobeckDirectorBuy2,000$22.04$44,080.00View SEC Filing  
3/9/2015Jack W SchulerDirectorBuy22,584$17.18$387,993.12View SEC Filing  
1/5/2015Jack W SchulerDirectorBuy18,000$18.93$340,740.00View SEC Filing  
9/22/2014Jack W SchulerDirectorBuy2,588$16.44$42,546.72View SEC Filing  
9/19/2014Jack W SchulerDirectorBuy32,411$16.67$540,291.37View SEC Filing  
8/21/2014Jack W SchulerDirectorBuy2,900$16.79$48,691.00View SEC Filing  
8/5/2014Larry N FeinbergMajor ShareholderBuy11,835$15.92$188,413.20View SEC Filing  
8/5/2014Matthew StrobeckDirectorBuy20,000$16.70$334,000.00View SEC Filing  
8/4/2014Matthew StrobeckDirectorBuy20,000$16.70$334,000.00View SEC Filing  
7/16/2014Larry N FeinbergMajor ShareholderBuy20,000$21.54$430,800.00View SEC Filing  
7/1/2014Jack W SchulerDirectorBuy8,698$25.70$223,538.60View SEC Filing  
6/30/2014Jack W SchulerDirectorBuy10,000$26.09$260,900.00View SEC Filing  
6/30/2014Larry N FeinbergMajor ShareholderBuy20,000$25.72$514,400.00View SEC Filing  
5/12/2014Larry N FeinbergMajor ShareholderBuy297,618$16.80$4,999,982.40View SEC Filing  
2/5/2014Larry N FeinbergMajor ShareholderBuy8,554$24.78$211,968.12View SEC Filing  
1/27/2014Larry N FeinbergMajor ShareholderBuy16,307$13.09$213,458.63View SEC Filing  
12/31/2013Larry N FeinbergMajor ShareholderBuy84,081$12.29$1,033,355.49View SEC Filing  
10/30/2013Larry N FeinbergMajor ShareholderBuy10,000$12.95$129,500.00View SEC Filing  
8/30/2013Larry N FeinbergMajor ShareholderBuy16,001$9.76$156,169.76View SEC Filing  
8/28/2013Larry N FeinbergMajor ShareholderBuy158,445$9.80$1,552,761.00View SEC Filing  
8/16/2013Jack W SchulerDirectorBuy78,494$7.88$618,532.72View SEC Filing  
8/14/2013Jack W SchulerDirectorBuy413,090$8.04$3,321,243.60View SEC Filing  
8/14/2013Larry N FeinbergMajor ShareholderBuy36,814$7.24$266,533.36View SEC Filing  
8/9/2013Larry N FeinbergMajor ShareholderBuy35,168$7.30$256,726.40View SEC Filing  
6/21/2013Larry N FeinbergMajor ShareholderBuy114,250$8.00$914,000.00View SEC Filing  
6/12/2013Larry N FeinbergMajor ShareholderBuy7,175$8.41$60,341.75View SEC Filing  
6/7/2013Larry N FeinbergMajor ShareholderBuy45,508$8.33$379,081.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Accelerate Diagnostics (NASDAQ:AXDX)
Latest Headlines for Accelerate Diagnostics (NASDAQ:AXDX)
Source:
DateHeadline
americanbankingnews.com logoAccelerate Diagnostics Inc (AXDX) Stock Rating Reaffirmed by BTIG Research
www.americanbankingnews.com - May 17 at 1:32 PM
globenewswire.com logoAccelerate Diagnostics Announces Closing of $79.3 Million Upsized Offering - GlobeNewswire (press release)
globenewswire.com - May 16 at 3:51 PM
finance.yahoo.com logoAccelerate Diagnostics Announces Closing of $79.3 Million Upsized Offering
finance.yahoo.com - May 16 at 12:24 PM
finance.yahoo.com logoETFs with exposure to Accelerate Diagnostics, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 4:16 PM
americanbankingnews.com logoTraders Purchase High Volume of Put Options on Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - May 14 at 9:14 AM
rttnews.com logoARRY Hits Trial Goals, DEPO Falls On Q1 Results, SAGE Awaits Data In Q3
www.rttnews.com - May 11 at 4:14 PM
globenewswire.com logoAccelerate Diagnostics Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - May 10 at 3:58 PM
streetinsider.com logoAccelerate Diagnostics (AXDX) Prices 2.75M Upsized Offering at $28.85/Sh - StreetInsider.com
www.streetinsider.com - May 10 at 3:58 PM
finance.yahoo.com logoAccelerate Diagnostics, Inc. :AXDX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 3:58 PM
finance.yahoo.com logoAccelerate Diagnostics Announces Pricing of Upsized Public Offering of Common Stock
finance.yahoo.com - May 10 at 8:59 AM
streetinsider.com logoAccelerate Diagnostics (AXDX) Commences 2.5M Offering of Common Stock - StreetInsider.com
www.streetinsider.com - May 9 at 3:48 PM
finance.yahoo.com logoAccelerate Diagnostics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - May 8 at 8:42 PM
americanbankingnews.com logoAccelerate Diagnostics Inc (AXDX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 8 at 5:28 PM
americanbankingnews.com logoAccelerate Diagnostics Inc (AXDX) Releases Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 3:36 PM
americanbankingnews.com logoFY2017 Earnings Estimate for Accelerate Diagnostics Inc Issued By William Blair (AXDX)
www.americanbankingnews.com - May 8 at 10:36 AM
americanbankingnews.com logoAccelerate Diagnostics Inc (AXDX) Sees Significant Increase in Short Interest
www.americanbankingnews.com - May 6 at 8:32 PM
marketbeat.com logoAccelerate Diagnostics reports 1Q loss
marketbeat.com - May 5 at 6:52 PM
americanbankingnews.com logoBrokerages Expect Accelerate Diagnostics Inc (AXDX) to Post ($0.27) Earnings Per Share
www.americanbankingnews.com - May 5 at 9:46 AM
globenewswire.com logoAccelerate Diagnostics Reports 191 Instruments Under Contract and 3x Revenue Growth for First Quarter 2017 - GlobeNewswire (press release)
globenewswire.com - May 4 at 1:51 AM
americanbankingnews.com logoAccelerate Diagnostics Inc (AXDX) Updates Q1 Earnings Guidance
www.americanbankingnews.com - May 4 at 1:12 AM
finance.yahoo.com logoAccelerate Diagnostics Reports 191 Instruments Under Contract and 3x Revenue Growth for First Quarter 2017 - Yahoo Finance
finance.yahoo.com - May 3 at 8:50 PM
finance.yahoo.com logoAccelerate Diagnostics Reports 191 Instruments Under Contract and 3x Revenue Growth for First Quarter 2017
finance.yahoo.com - May 3 at 8:50 PM
americanbankingnews.com logoAccelerate Diagnostics Inc (AXDX) Issues Q1 Earnings Guidance
www.americanbankingnews.com - May 3 at 7:56 PM
finance.yahoo.com logoETFs with exposure to Accelerate Diagnostics, Inc. : May 3, 2017
finance.yahoo.com - May 3 at 3:49 PM
finance.yahoo.com logoInvestor Network: Accelerate Diagnostics, Inc. to Host Earnings Call
finance.yahoo.com - May 3 at 11:52 AM
americanbankingnews.com logoAccelerate Diagnostics (AXDX) Earning Somewhat Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - May 2 at 12:26 PM
americanbankingnews.com logoPositive Media Coverage Extremely Likely to Affect Accelerate Diagnostics (AXDX) Share Price
www.americanbankingnews.com - April 28 at 9:48 AM
americanbankingnews.com logoAccelerate Diagnostics (AXDX) Receives News Impact Rating of 0.22
www.americanbankingnews.com - April 24 at 6:02 PM
finance.yahoo.com logoImplied Volatility Surging for Accelerate Diagnostics (AXDX) Stock Options
finance.yahoo.com - April 24 at 10:21 AM
americanbankingnews.com logoStock Traders Buy High Volume of Put Options on Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - April 23 at 7:10 AM
americanbankingnews.com logoAccelerate Diagnostics (AXDX) Receiving Somewhat Positive Press Coverage, Study Shows
www.americanbankingnews.com - April 21 at 11:39 AM
americanbankingnews.com logo Analysts Set $29.00 Price Target for Accelerate Diagnostics Inc (AXDX)
www.americanbankingnews.com - April 20 at 11:25 AM
finance.yahoo.com logoAccelerate Diagnostics Schedules Call to Review First Quarter 2017 Results for May 3rd
finance.yahoo.com - April 19 at 10:23 AM
finance.yahoo.com logoAccelerate Diagnostics, Inc. – Value Analysis (NASDAQ:AXDX) : April 17, 2017
finance.yahoo.com - April 17 at 3:42 PM
finance.yahoo.com logoAccelerate Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : AXDX-US : April 13, 2017
finance.yahoo.com - April 13 at 3:56 PM
americanbankingnews.com logoSomewhat Favorable Press Coverage Extremely Likely to Impact Accelerate Diagnostics (AXDX) Stock Price
www.americanbankingnews.com - April 13 at 8:52 AM
americanbankingnews.com logoZacks: Accelerate Diagnostics Inc (AXDX) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 5 at 9:31 AM
americanbankingnews.com logo Accelerate Diagnostics Inc (AXDX) Receives Average Rating of "" from Brokerages
www.americanbankingnews.com - March 21 at 11:52 AM
streetinsider.com logoForm 8-K Accelerate Diagnostics, For: Mar 14
www.streetinsider.com - March 20 at 4:04 PM
biz.yahoo.com logoACCELERATE DIAGNOSTICS, INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
biz.yahoo.com - March 20 at 9:49 AM
streetinsider.com logoAccelerate Diagnostics (AXDX) Appoints Tom Brown to Board - StreetInsider.com
www.streetinsider.com - March 16 at 2:02 AM
streetinsider.com logoAccelerate Diagnostics (AXDX) Appoints Tom Brown to Board
www.streetinsider.com - March 15 at 4:01 PM
finance.yahoo.com logoAccelerate Diagnostics Names Tom Brown to Board of Directors
finance.yahoo.com - March 15 at 4:01 PM
finance.yahoo.com logoIs the Options Market Predicting a Spike in Accelerate Diagnostics (AXDX) Stock?
finance.yahoo.com - March 14 at 3:39 PM
biz.yahoo.com logoACCELERATE DIAGNOSTICS, INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 13 at 3:54 PM
finance.yahoo.com logoACCELERATE DIAGNOSTICS, INC Financials
finance.yahoo.com - March 3 at 3:59 PM
biz.yahoo.com logoACCELERATE DIAGNOSTICS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financia
biz.yahoo.com - March 1 at 8:44 PM
biz.yahoo.com logoACCELERATE DIAGNOSTICS, INC Files SEC form 10-K, Annual Report
biz.yahoo.com - February 28 at 11:28 AM
nasdaq.com logoAccelerate Diagnostics (AXDX) Looks Good: Stock Up 7.5% - Nasdaq - Nasdaq
www.nasdaq.com - February 27 at 3:48 PM
biz.yahoo.com logoQ4 2016 Accelerate Diagnostics Inc Earnings Release - After Market Close
us.rd.yahoo.com - February 27 at 9:38 AM

Social

Accelerate Diagnostics (AXDX) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff